Invega utilizes the active compound paliperidone, a metabolite of risperidone. It works by targeting various receptors in the brain, including dopamine D2 and serotonin 5-HT2A receptors. This action helps stabilize mood and reduce psychotic symptoms.
Unlike standard antipsychotics, Invega is designed for once-daily administration, facilitating easier adherence to treatment regimens. Its extended-release formulation allows for the gradual release of medication, minimizing peak-related side effects and providing a more even therapeutic effect throughout the day.